{"id":"cj-plasma-solution-a-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Infection risk (pathogen transmission)"},{"rate":null,"effect":"Volume overload"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a plasma-based injectable, this solution contains multiple coagulation factors, albumin, and immunoglobulins that work synergistically to restore hemostatic function and provide nutritional/immunological support. The exact composition and mechanism are proprietary to Seoul National University Hospital, but plasma solutions are typically used to correct coagulopathy, replace lost blood volume, and support wound healing or recovery in critical conditions.","oneSentence":"CJ Plasma Solution A is a plasma-derived therapeutic that replenishes coagulation factors and other plasma proteins to support hemostasis and tissue repair.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:09.127Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Coagulopathy and hemostatic support (Phase 3 indication under investigation)"}]},"trialDetails":[{"nctId":"NCT03699462","phase":"PHASE4","title":"The Effect of Balanced Crystalloid Versus 5% Albumin on Endothelial Glycocalyx Degradation in Patients Undergoing Off-pump Coronary Artery Bypass Surgery","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2018-11-13","conditions":"Coronary Artery Occlusive Disease(CAOD)","enrollment":106},{"nctId":"NCT02799368","phase":"PHASE3","title":"Balanced Salt Solution Versus 0.9% Saline Infusion for Prevention of Contrast-induced Acute Kidney Injury (BASIC Trial)","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-11","conditions":"Acute Kidney Injury, Renal Insufficiency, Chronic, Contrast Media Reaction","enrollment":493},{"nctId":"NCT01898975","phase":"","title":"A Gray Zone Approach to Stroke Volume Variation Derived From NICOM","status":"WITHDRAWN","sponsor":"Samsung Medical Center","startDate":"2013-06","conditions":"Neurological Diseases or Conditions, Fluid Responsiveness, Non Invasive Cardiac Output Monitoring","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CJ Plasma Solution A Injection","genericName":"CJ Plasma Solution A Injection","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CJ Plasma Solution A Injection is being studied as a potential treatment for various conditions, including Coronary Artery Occlusive Disease, Acute Kidney Injury, Renal Insufficiency, Contrast Media Reaction, and Neurological Diseases or Conditions. The exact mechanism of CJ Plasma Solution A Injection is not specified in the provided information, but it is being compared to 5% Albumin in clinical trials.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}